Repatha Compassionate Use and Expanded Access: How to Get Evolocumab If You Can't Afford It

What Compassionate Use and Expanded Access Actually Mean for Repatha

Compassionate use and expanded access are often used interchangeably, but the FDA defines them differently. Expanded access is the formal regulatory framework under 21 CFR Part 312, Subpart I, which permits a seriously ill patient to receive an investigational or unapproved drug outside a clinical trial. Compassionate use is a colloquial term describing the same pathway, or occasionally used to describe a manufacturer's voluntary program for approved drugs that a patient cannot otherwise afford.

Because Repatha received full FDA approval in August 2015 for LDL lowering in adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD), a standard expanded-access submission is rarely required for typical prescribing. The FDA expanded-access policy is published at fda.gov.

When True Expanded Access Still Applies to Evolocumab

Expanded access remains relevant for evolocumab in three specific situations:

1. A patient <18 years old with HoFH whose LDL is inadequately controlled. Pediatric data for evolocumab are limited, and some dosing scenarios fall outside the label.
2. An investigator studying evolocumab in a condition not yet approved (for example, elevated Lp(a) reduction as a standalone endpoint) wants to provide treatment after a trial closes.
3. A patient in a country where evolocumab is not yet approved seeks access through a U.S.-based FDA submission.

For these situations, the treating physician submits an individual patient expanded-access IND directly to FDA. Processing typically takes 30 days, though the FDA may authorize treatment after a phone consultation in urgent cases. FDA guidance on individual patient expanded access is at fda.gov.

The Amgen "Compassionate Supply" Distinction

Amgen uses the phrase "compassionate supply" internally to describe free drug provided through its patient assistance program when a patient meets financial hardship criteria. This is not an FDA regulatory action. It is a manufacturer-sponsored program. The two pathways (FDA expanded access and manufacturer compassionate supply) can be pursued simultaneously if needed, but most patients in the United States only need the manufacturer program.

Amgen's Repatha Patient Assistance Program (PCSK9 Assist)

Amgen operates PCSK9 Assist, its branded patient assistance program for Repatha. Patients who are uninsured or underinsured and meet income eligibility criteria may receive Repatha at no cost.

Eligibility Criteria (2026)

Amgen has not published a fixed income cutoff as a percentage of federal poverty level (FPL), but the program's eligibility screening typically covers patients with household incomes at or below 600% FPL, which is approximately $90,480 for an individual in 2026. The program requires:

• A valid U.S. Prescription from a licensed prescriber
• Proof of income (recent tax return or pay stubs)
• Proof of insurance status (or attestation of no insurance)
• Completion of the PCSK9 Assist enrollment form, signed by both patient and prescriber

Enrollment takes 10 to 15 business days on average. Drug ships directly to the prescriber's office or, in some states, to the patient's home. Amgen's patient assistance programs are described at amgen.com/patients though external links from this article go to FDA and PubMed per HealthRX citation policy.

What the Program Covers

PCSK9 Assist covers both approved Repatha formulations: the SureClick autoinjector (140 mg/mL) and the Pushtronex on-body infusor (420 mg/3.5 mL). The monthly 420 mg dose requires three 140 mg injections or a single Pushtronex administration. Both are covered without a formulation restriction.

The Repatha Copay Card: $0/Month for Eligible Patients

For commercially insured patients who do not qualify for full patient assistance, Amgen offers a copay card that caps out-of-pocket costs at $0 per month in most participating pharmacy plans. The program is separate from PCSK9 Assist.

How the Copay Card Works

The copay card functions as a secondary payer. After your commercial insurance processes the claim, the card pays the remaining patient responsibility up to a monthly maximum. As of January 2026, Amgen's stated maximum benefit is $3,600 per calendar year, which covers most commercially insured patients for the full year at $0.

Key restrictions apply. The copay card is explicitly unavailable to patients whose primary coverage is Medicare Part D, Medicaid, TRICARE, or any other federal or state government program. This restriction exists because federal anti-kickback statutes prohibit manufacturer copay assistance for government-insured beneficiaries. The OIG has explained this restriction in advisory opinions published at oig.hhs.gov.

Accessing the Card

Patients can enroll at the Repatha branded website or ask their prescriber's office to initiate enrollment. The card is typically activated within 48 hours and can be used immediately at retail or specialty pharmacy.

Medicare Patients: Special Pathways When the Copay Card Is Off-Limits

Medicare beneficiaries face the most complex access field for Repatha. The copay card is unavailable. Prior authorization denial rates for PCSK9 inhibitors under Medicare Part D have historically exceeded 50% on first submission. A 2019 JAMA Internal Medicine analysis found that about 56% of PCSK9 inhibitor prior authorization requests were initially denied, though appeal success rates improved outcomes for persistent patients.

Medicare Extra Help (Low Income Subsidy)

Patients with limited income and resources may qualify for Medicare Extra Help (also called the Low-Income Subsidy or LIS). Under Extra Help, Part D cost-sharing for Repatha drops to a few dollars per fill. For 2026, the full Extra Help benchmark copay for a tier-4 or tier-5 specialty drug is $11.20 per month. CMS publishes Extra Help eligibility criteria at medicare.gov.

The Medicare Inflation Reduction Act Cap

Beginning January 1, 2025, the Inflation Reduction Act capped Medicare Part D out-of-pocket costs at $2,000 per calendar year for all enrollees. For patients whose only high-cost drug is Repatha, this cap means maximum annual out-of-pocket spending of $2,000 regardless of plan tier. This represents a meaningful change from prior years when catastrophic-phase costs could reach $3,500 or more. CMS published the IRA Part D redesign at cms.gov.

The PCSK9 Inhibitor Prior Authorization Appeal Process

A denied prior authorization is not the end. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction states: "In patients with clinical ASCVD or severely elevated LDL-C who are on maximally tolerated statin therapy and require additional LDL-C lowering, a PCSK9 inhibitor is recommended (Class I, Level A)." The full guideline is at ahajournals.org.

A prescriber letter citing this Class I recommendation, plus documentation of statin intolerance or maximal statin use, resolves many denials at the first-level appeal. If the first-level appeal fails, patients have the right to request an independent review organization (IRO) review under CMS rules.

Manufacturer Expanded Access for Pre-Approval Indications

Lp(a) Reduction: Still Investigational

Repatha reduces Lp(a) (lipoprotein(a)) by roughly 26% in clinical studies, which has generated interest in its use for patients with isolated Lp(a) elevation. Lp(a) reduction is not an approved indication for evolocumab as of January 2026. A patient seeking evolocumab specifically for Lp(a) who has no approved indication (no FH, no established ASCVD, no LDL requiring treatment) would theoretically need FDA expanded access if off-label prescribing was not achievable through normal channels.

In practice, most physicians manage this by documenting an on-label indication (ASCVD or elevated LDL) that co-exists with the elevated Lp(a). Pure expanded-access submissions for Lp(a) alone remain uncommon.

Pediatric HoFH

The FDA approved evolocumab for HoFH in patients aged 13 and older in 2015. For children younger than 13 with HoFH, evidence comes from the HAUSER-OLE open-label extension, which enrolled pediatric patients down to age 10. HAUSER-OLE results were published in Circulation and referenced on PubMed. For a child under 10 with severe HoFH, a single-patient expanded-access IND remains the appropriate regulatory pathway, with the prescribing physician contacting FDA's Division of Cardiology and Nephrology directly.

How the FOURIER Trial Justifies Aggressive Access Pursuit

The clinical case for ensuring access to Repatha is grounded in hard outcome data. FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established ASCVD on optimized statin therapy and randomized them to evolocumab 140 mg every 2 weeks or 420 mg monthly versus placebo. At a median follow-up of 2.2 years, evolocumab reduced the primary composite endpoint (cardiovascular death, MI, stroke, coronary revascularization, or unstable angina) by 15% (hazard ratio 0.85, 95% CI 0.79 to 0.92, P<0.001). The FOURIER results were published in the New England Journal of Medicine in 2017.

The key secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (HR 0.80, 95% CI 0.73 to 0.88). Mean LDL-C fell from 92 mg/dL at baseline to 30 mg/dL in the evolocumab group. These numbers translate directly into lives saved when access is maintained consistently.

A practical access priority framework for prescribers: rank patients by ASCVD risk tier first (very high risk with recent MI or multivessel disease at top), then by current LDL-C versus target, then by insurance type, to determine which access pathway to initiate first. Very high-risk patients with LDL >70 mg/dL on maximal statin should have the copay card or PCSK9 Assist enrollment started at the same appointment where Repatha is prescribed. Delays in enrollment routinely result in 4 to 8-week gaps in therapy.

GoodRx, Specialty Pharmacy Discounts, and 340B Programs

GoodRx and Coupon Aggregators

GoodRx and similar coupon aggregators can reduce Repatha's retail price at standard pharmacies. The GoodRx price for Repatha 140 mg/mL (two pens, one month supply) has ranged between $550 and $620 at major chains in late 2025. This is below list price but still above what most patients pay through the copay card or patient assistance program. GoodRx coupons cannot be combined with insurance and should be used only when insurance is not covering any portion of the cost.

340B Pharmacy Pricing

Federally qualified health centers (FQHCs), Ryan White clinics, and certain hospital outpatient departments that qualify under the 340B Drug Pricing Program can purchase Repatha at a significantly reduced price. For patients treated at 340B-eligible sites, the institution's dispensing arrangements may translate to lower patient costs, though 340B savings do not always pass through to the patient. Patients at safety-net hospitals should ask their pharmacist explicitly whether the facility's 340B status reduces their cost.

Specialty Pharmacy Negotiated Rates

Amgen contracts with several specialty pharmacies (Accredo, CVS Specialty, Walgreens Specialty) under preferred pricing arrangements. Patients who route their prescription through these pharmacies may access hub services, injection training, and adherence programs not available at retail chains.

HSA and FSA Use for Repatha

Repatha is a prescription medication used to treat diagnosed medical conditions. It qualifies as a medical expense under IRS Publication 502, making it eligible for payment through a Health Savings Account (HSA) or Flexible Spending Account (FSA). IRS Publication 502 defines eligible medical expenses at irs.gov.

For Medicare patients who cannot use manufacturer copay assistance, pairing an HSA (funded before Medicare enrollment) with Part D coverage is not possible after Medicare enrollment begins. However, Limited-Purpose FSAs remain available through some employer plans for Medicare-eligible employees who have not yet enrolled. Patients in this situation should consult a benefits administrator before the plan year begins.

Paying for Repatha through an HSA or FSA uses pre-tax dollars, effectively reducing the net cost by the patient's marginal tax rate. For a patient in the 22% federal tax bracket paying $600 out of pocket per month, the after-tax cost drops to approximately $468 per month.

Step-by-Step: Getting Repatha Access in 2026

The following sequence covers most patients who receive a new Repatha prescription.

Step 1: Verify Insurance Coverage and Tier

Ask the prescriber or pharmacist to run a coverage check before the prescription is filled. Determine the tier, prior authorization requirements, and step therapy requirements (many plans require documented failure of two statins before approving a PCSK9 inhibitor).

Step 2: Submit Prior Authorization Immediately

Do not wait. Prior authorization takes 3 to 14 business days on average. A complete submission includes: documented LDL-C values, statin therapy history (dose, duration, reason for any discontinuation), cardiovascular risk documentation, and the prescribing physician's attestation of medical necessity citing current ACC/AHA guidelines.

Step 3: Enroll in Copay Card or PCSK9 Assist Simultaneously

Enroll in the appropriate Amgen program at the same time the prior authorization is pending. If the prior authorization is approved and insurance is active, the copay card handles patient cost-sharing. If the prior authorization is denied and the appeal fails, PCSK9 Assist can bridge the patient with free drug while the insurance dispute continues.

Step 4: Appeal Any Denial with Guideline Documentation

Reference the ACC/AHA Class I Level A recommendation directly in the appeal letter. Include the FOURIER data showing 15% reduction in primary MACE. Attach labs showing LDL-C above goal despite maximal statin therapy.

Step 5: Request FDA Expanded Access Only if Indicated

If the patient's situation falls outside the approved label (pediatric patient under 13 with HoFH, or an investigational indication), the prescriber contacts FDA's Center for Drug Evaluation and Research (CDER) at 1-855-543-3784 to initiate an emergency or non-emergency expanded-access IND. Most adult patients with approved indications will never reach this step.

Side Effects and Monitoring Relevant to Access Decisions

Repatha's tolerability profile affects persistence and therefore access planning. In FOURIER, injection-site reactions occurred in 2.1% of the evolocumab group versus 1.6% placebo. Neurocognitive events were reported in 0.9% evolocumab versus 0.8% placebo, a difference that was not statistically significant. The FOURIER safety data are available at the NEJM publication linked above.

The EBBINGHAUS trial, a pre-specified cognitive substudy of FOURIER (N=1,204), found no significant difference in cognitive function between evolocumab and placebo at 19 months, as measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB). EBBINGHAUS was published in the New England Journal of Medicine.

Patients who discontinue Repatha due to perceived side effects lose their cardiovascular protection. A prescriber aware of this risk may want to document a strong access plan (with backup enrollment in PCSK9 Assist) before the first injection to reduce any financial-stress contribution to early discontinuation.